Insulin-like Growth Factor 1 and Adiponectin and Associations with Muscle Deficits, Disease Characteristics, and Treatments in Rheumatoid Arthritis.

TitleInsulin-like Growth Factor 1 and Adiponectin and Associations with Muscle Deficits, Disease Characteristics, and Treatments in Rheumatoid Arthritis.
Publication TypeJournal Article
Year of Publication2015
AuthorsBaker JF, Von Feldt JMarie, Mostoufi-Moab S, Kim W, Taratuta E, Leonard MB
JournalJ Rheumatol
Volume42
Issue11
Pagination2038-45
Date Published2015 Nov
ISSN0315-162X
KeywordsAbsorptiometry, Photon, Adiponectin, Adolescent, Adult, Age Factors, Aged, Antirheumatic Agents, Arthritis, Rheumatoid, Biomarkers, Body Composition, Body Mass Index, Cohort Studies, Female, Humans, Insulin-Like Growth Factor I, Linear Models, Male, Middle Aged, Multivariate Analysis, Muscle Weakness, Muscular Atrophy, Prognosis, Prospective Studies, Risk Assessment, Severity of Illness Index, Sex Factors, Treatment Outcome, Young Adult
Abstract

OBJECTIVE: Rheumatoid arthritis (RA) is associated with low muscle mass and density. The objective of our study was to evaluate associations between 2 serum biomarkers [insulin-like growth factor 1 (IGF-1) and adiponectin] and skeletal muscle in RA.

METHODS: Whole-body dual energy X-ray absorptiometry measures of the appendicular lean mass index (ALMI; kg/m(2)) and total fat mass index (kg/m(2)), as well as the peripheral quantitative computed tomography measures of the lower leg muscle and fat cross-sectional area (CSA; cm(2)) and muscle density (an index of fat infiltration) were obtained from 50 participants with RA, ages 18-70 years. Multivariable linear regression analyses evaluated associations between body composition and levels of adiponectin and IGF-1, adjusted for age, sex, and adiposity.

RESULTS: Greater age was associated with higher adiponectin (p = 0.06) and lower IGF-1 (p = 0.004). Eight subjects had IGF-1 levels below the reference range for their age and sex. These subjects had significantly lower ALMI and muscle CSA in multivariable models. Lower IGF-1 levels were associated with greater clinical disease activity and severity, as well as low ALMI, muscle CSA, and muscle density (defined as 1 SD below normative mean). After adjusting for age and sex, greater adiponectin levels were associated with lower BMI (p = 0.02) as well as lower ALMI, and lower muscle CSA, independent of adiposity (p < 0.05). Only greater Health Assessment Questionnaire scores were significantly associated with lower adiponectin levels.

CONCLUSION: Low IGF-1 and greater adiponectin levels are associated with lower muscle mass in RA. Lower IGF-1 levels were seen in subjects with greater disease activity and severity.

DOI10.3899/jrheum.150280
Alternate JournalJ. Rheumatol.
PubMed ID26329340
PubMed Central IDPMC4809051
Grant ListVA999999 / / Intramural VA / United States
R01 DK064966 / DK / NIDDK NIH HHS / United States
IK2 CX000955 / CX / CSRD VA / United States
K07 CA166177 / CA / NCI NIH HHS / United States
K24 DK076808 / DK / NIDDK NIH HHS / United States
UL1 RR024134 / RR / NCRR NIH HHS / United States